drugset / Trial / NCT01843894
A Phase 1/2, RU-101 Ophthalmic Solution in Patients With Severe Dry Eye
RandomizedSingle-groupDouble-blindTreatment
Summary
Objectives: Primary * To determine the safety and tolerability of escalating doses of RU-101 for 4 weeks in patients with severe dry eye Secondary * To explore the efficacy of RU-101 * To explore optimal endpoints for future studies
Timeline
- Start
- 2013-04
- Primary completion
- 2014-07
- Completion
- 2014-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | RU-101 | Protein / enzyme biologic | 5 % | Topical |
| Subject | RU-101 | Protein / enzyme biologic | 10 % | Topical |
| Subject | RU-101 | Protein / enzyme biologic | 15 % | Topical |